Our client Aegros recently published an eyebrow-raising article outlining the larger truth surrounding the COVID-19 vaccines.

The article opens with;

"Hyperimmunes and vaccines work hand-in-glove. We require both of these treatment modalities to protect society from the ravages of a virus like COVID-19."

With vaccination being the popular topic for the mass media, there are very few sources of information that explain the big picture. Aegros simplifies it in their article;

Hyperimmunes
Hyperimmunes transfer the antibodies from someone who has developed immunity to an infection into a recipient who does not have that immunity. Hyperimmunes provide the recipient with immediate protection. Hyperimmunes are said to provide ‘passive immunity’ as the immunity is passed onto the recipient rather than your own body developing the immunity.

Vaccines
Vaccines use an external source to stimulate our immune system to respond to an infection. It takes time for the body to achieve protection, in the case of current information available regarding Covid-19 vaccines, up to 28 days. Vaccines are designed to spur our immune system to make an immunological response and for this reason are said to provide ‘active immunity’.

In our perception, hyperimmunisation seems to be the immediate solution while we wait for the COVID-19/20 vaccines to be perfected over time. If you're still not convinced;

Why do you need Hyperimmunes when you have a vaccine?
While an effective vaccine(s) will hopefully eventually provide the best chance of controlling the COVID-19 pandemic, it is sadly not so simple. No vaccine will be perfect, and no vaccine will provide total protection for all recipients. No vaccine will end the pandemic instantly. The first vaccines are also likely to have significant limitations about which we will gradually learn. At this stage, important unresolved issues include

• vaccine performance for different groups: elderly, ethnic backgrounds, medical conditions

• duration of protection: duration of immunity, effectiveness against evolving virus strains

• the overall balance of benefit against harms

Because Aegros understands the importance of hyperimmunes comprehensively, they have developed their own COVID-19 hyperimmune called Covimmune™.

Why does Aegros believe its Covimmune™ will be successful?
Aegros has developed its Covid-19 hyperimmune called Covimmune™ to provide passive protection for frontline healthcare workers. No other hyperimmune in development is looking to protect frontline health workers using passive immunity. The Company believes it has a natural advantage in this market because:

• First to Market. Aegros is the only organisation currently undertaking a clinical trial of a hyperimmune to provide passive immunity for frontline healthcare workers. This means Covimmune™ should be first to market in early 2021.

• Low Cost Producer. Aegros’ HaemaFrac™ process enables the Company to produce 4 doses of Covimmune™ per litre of convalescent plasma compared to 2 using the Chon process. This makes Aegros the industry low cost producer.

• Small Volume Producer Using the HaemaFrac™ Aegros can process as little as 20 litres, whereas the existing fractionators require 1,000 litres per batch. As Covid-19 plasma is hard to source this is a real time to market advantage for Aegros.

Read the complete Aegros article here.

Interested to find out more investor information on Aegros?